We @RedefiningMECFS and @AvikRoy74969264 are excited to share some early results of our low dose rapamycin project in its pre-print version here. Thanks to all the patients for participating!

researchsquare.com/article/rs-659… We found that a significant proportion of the patients who finished the three month trial period of rapamycin (an mTOR inhibitor) showed improvements in both clinical features of the illness (PEM) and saw improvement in blood based markers of autophagy function